Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.
about
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problemsManagement of antipsychotic-related weight gainPharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysisSystematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis.Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.Interventions for the metabolic syndrome in schizophrenia: a reviewRole of Omega-3 fatty acids in preventing metabolic disturbances in patients on olanzapine plus either sodium valproate or lithium: a randomized double-blind placebo-controlled trial.Can metformin or rosiglitazone reduce metabolic side effects associated with atypical antipsychotics?Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis.Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C.Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain.A novel insulin sensitizer drug candidate-BGP-15-can prevent metabolic side effects of atypical antipsychotics.Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats.
P2860
Q24235450-680FEA76-DEBF-45DD-BEA1-39DFF6215932Q24610124-10FF16A9-ECA1-4C42-B14C-68150D62A4DDQ27692023-0366EEC6-9AEE-45F1-AFB8-F55F1034B9C6Q30459096-5635E6B1-B7B1-491C-B8CE-AFD6E9EB8A3EQ34315836-85FB0039-808C-40D9-8391-3B1A04C58180Q34661011-C6B41EAC-322F-4978-94A8-C8CA0ED18C92Q36034676-67661A1B-9F59-4899-B7D2-F97948CD52BEQ36240230-E90BCAFC-DA54-4813-BCD0-1D5A1612AFC3Q36377890-7C9012EC-7320-465B-8D25-CD1D0732EA4EQ36383322-0ECF9E89-C0DE-4304-B4FE-D1A6E197A365Q36401248-25169E2B-ED45-41CD-B76F-B9F183FD7919Q36564507-A72086A6-2B44-406F-92FB-5ECD4F5384A9Q37633560-DD554EA5-F1B1-42A3-BBE3-8E7405F35245Q37676725-B081B086-5892-4B5A-A559-C67ED6A92205Q37710237-9BB23BAE-2E15-4EEE-86F3-DC0D8E15D656Q47194413-6249A49B-E837-4EEA-8A80-DF48D1B0A53DQ47213104-9C0938E6-816B-49D2-8011-D32DA58EAF6DQ47441084-95BBD544-A960-4B46-8E05-4C8410BAC4E9Q47762878-17BD44E2-45E5-491D-968E-2CAEE5B50653
P2860
Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Rosiglitazone in the assistanc ...... ebo-controlled, 12-week trial.
@en
Rosiglitazone in the assistanc ...... ebo-controlled, 12-week trial.
@nl
type
label
Rosiglitazone in the assistanc ...... ebo-controlled, 12-week trial.
@en
Rosiglitazone in the assistanc ...... ebo-controlled, 12-week trial.
@nl
prefLabel
Rosiglitazone in the assistanc ...... ebo-controlled, 12-week trial.
@en
Rosiglitazone in the assistanc ...... ebo-controlled, 12-week trial.
@nl
P2093
P356
P1433
P1476
Rosiglitazone in the assistanc ...... ebo-controlled, 12-week trial.
@en
P2093
E Araujo de Baptista
E Uzcátegui
S Beaulieu
T Baptista
T Galeazzi
Y El Fakih
P356
10.1055/S-0028-1085438
P577
2009-01-19T00:00:00Z